Medical imaging has revolutionized Europe’s healthcare, from diagnostics to treatment plans, and it is nowadays impossible to imagine a contemporary healthcare system without its benefits. In the last decades, technological developments have been at the core of new imaging modalities, driving existing modalities with known physics principles to new levels (e.g. low dose or spectral CT), enabling new routine clinical tools (e.g. diffusion tensor imaging), and opening new avenues for research, diagnostic and treatment. However, lack of sensitivity, low spatial resolution or even accessibility to devices all still hinder the applicability of medical imaging to address the major healthcare challenges of an ageing Europe.
people in Europe are affected by at least one brain disease such as Alzheimer’s, Parkinson’s, dementia, stroke etc.
Most neurological diseases are aging sensitive and with the ongoing demographic changes, their incidence is expected to increase.
This will be one of the major societal challenges in Europe and worldwide.
Stroke alone is the second most common cause of death and the third leading cause of disability worldwide.
of strokes are of the ischaemic subtype that can be treated by restoring blood flow to the ischaemic brain through thrombolysis or thrombectomy
but only within a relatively narrow time window of 4.5–7.3 hours after ischemic onset.
The evolution of ischaemic damage varies much among patients and a careful selection of the patient’s treatment path, based on imaging properties of the ischaemic brain, is essential to achieve significant improvement in the outcome. In the challenging move away from 'one size fits all’ to personalized medicine, a multidisciplinary approach is required. In that context, molecular imaging, at the cellular and molecular levels, of the processes involved in these diseases is essential. However, despite undergoing steady developments, current efforts in medical imaging (especially for the brain) rely on bulky, expensive, and complex high-field MRI or hybrid PET-MRI or PET-CT scanners. The GAMMA-MRI (γMRI) project goes beyond current technological paradigms in brain imaging.
γMRI will develop a working prototype for in vivo molecular imaging, based on a revolutionary technology, allowing the simultaneous exploitation of the sensitivity of gamma (γ) detection and the spatial resolution and flexibility of MRI. γMRI is not just a hybrid approach combining separate modalities but a single new modality, simultaneously achieving the high spatial resolution of MRI and the high sensitivity of PET with faster scan times. Not requiring ultra-high MRI magnetic fields and expensive EM shielded rooms, nor detection of coincidence γ rays as in PET. γMRI will be less complex and thus less expensive than present state-of-the-art devices, especially hybrid ones. This disruptive approach of a more accurate and widely available molecular imaging technology will pave new ways for patient care and medical imaging market.